MovDisordV3, PascalFrancis, Corpus, bibRecord, 001F59

Sydney multicenter study of Parkinson's disease : Non-L-dopa-responsive problems dominate at 15 years

Identifieur interne : 001F59 ( PascalFrancis/Corpus ); précédent : 001F58; suivant : 001F60

Sydney multicenter study of Parkinson's disease : Non-L-dopa-responsive problems dominate at 15 years

Auteurs : Mariese A. Hely ; John G. L. Morris ; Wayne G. J. Reid ; Robert Trafficante

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0151001

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Etude multicentrique, Lévodopa, Parkinson maladie.

English descriptors

KwdEn :
- Levodopa, Multicenter study, Nervous system diseases, Parkinson disease.

Abstract

One-third of the 149 people recruited 15 to 18 years ago in the Sydney Multicentre Study of Parkinson's disease have survived. The original study compared low-dose levodopa with low-dose bromocriptine. We now report the problems experienced by people who survive 15 years from diagnosis. The standardized mortality ratio is significantly elevated at 1.86 and is not significantly different between treatment arms. Falls occur in 81% of patients, and 23% sustained fractures. Cognitive decline is present in 84%, and 48% fulfill the criteria for dementia. Hallucinations and depression are experienced by 50%. Choking has occurred in 50%, symptomatic postural hypotension in 35%, and urinary incontinence in 41%. No patient is still employed, and 40% of patients live in aged care facilities. Although approximately 95% have experienced L-dopa-induced dyskinesia/dystonia and end of dose failure of medication, in the majority, these symptoms are not disabling. Dyskinesia and dystonia were delayed by early use of bromocriptine, but end-of-dose failure appeared at a similar time once L-dopa was added. The rate of disease progression is similar in both arms of the study. We conclude that the most disabling long-term problems of Parkinson's disease relate to the emergence of symptoms that are not improved by L-dopa. Neuroprotective interventions in Parkinson's disease should be judged by their ability to improve non-L-dopa-responsive aspects of the disease, rather than just by their capacity to delay the introduction of L-dopa or reduce its associated side effects.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 20`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Sydney multicenter study of Parkinson's disease : Non-L-dopa-responsive problems dominate at 15 years`
A11	`01`	`1`		`@1 HELY (Mariese A.)`
A11	`02`	`1`		`@1 MORRIS (John G. L.)`
A11	`03`	`1`		`@1 REID (Wayne G. J.)`
A11	`04`	`1`		`@1 TRAFFICANTE (Robert)`
A14	`01`			`@1 Department of Neurology, Westmead Hospital @2 Westmead New South Wales @3 AUS @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A14	`02`			`@1 Covance Pty Ltd @2 Ainslie, Australian Capital Territory @3 AUS @Z 4 aut.`
A20				`@1 190-199`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000126378730080`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 67 ref.`
A47	`01`	`1`		`@0 05-0151001`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 One-third of the 149 people recruited 15 to 18 years ago in the Sydney Multicentre Study of Parkinson's disease have survived. The original study compared low-dose levodopa with low-dose bromocriptine. We now report the problems experienced by people who survive 15 years from diagnosis. The standardized mortality ratio is significantly elevated at 1.86 and is not significantly different between treatment arms. Falls occur in 81% of patients, and 23% sustained fractures. Cognitive decline is present in 84%, and 48% fulfill the criteria for dementia. Hallucinations and depression are experienced by 50%. Choking has occurred in 50%, symptomatic postural hypotension in 35%, and urinary incontinence in 41%. No patient is still employed, and 40% of patients live in aged care facilities. Although approximately 95% have experienced L-dopa-induced dyskinesia/dystonia and end of dose failure of medication, in the majority, these symptoms are not disabling. Dyskinesia and dystonia were delayed by early use of bromocriptine, but end-of-dose failure appeared at a similar time once L-dopa was added. The rate of disease progression is similar in both arms of the study. We conclude that the most disabling long-term problems of Parkinson's disease relate to the emergence of symptoms that are not improved by L-dopa. Neuroprotective interventions in Parkinson's disease should be judged by their ability to improve non-L-dopa-responsive aspects of the disease, rather than just by their capacity to delay the introduction of L-dopa or reduce its associated side effects.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Etude multicentrique @5 02`
C03	`02`	`X`	`ENG`	`@0 Multicenter study @5 02`
C03	`02`	`X`	`SPA`	`@0 Estudio multicéntrico @5 02`
C03	`03`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 03`
C03	`03`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 03`
C03	`03`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 03`
C03	`04`	`X`	`FRE`	`@0 Parkinson maladie @5 04`
C03	`04`	`X`	`ENG`	`@0 Parkinson disease @5 04`
C03	`04`	`X`	`SPA`	`@0 Parkinson enfermedad @5 04`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Antiparkinsonien @5 41`
C07	`05`	`X`	`ENG`	`@0 Antiparkinson agent @5 41`
C07	`05`	`X`	`SPA`	`@0 Antiparkinsoniano @5 41`
N21				`@1 101`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 05-0151001 INIST
ET :	Sydney multicenter study of Parkinson's disease : Non-L-dopa-responsive problems dominate at 15 years
AU :	HELY (Mariese A.); MORRIS (John G. L.); REID (Wayne G. J.); TRAFFICANTE (Robert)
AF :	Department of Neurology, Westmead Hospital/Westmead New South Wales/Australie (1 aut., 2 aut., 3 aut.); Covance Pty Ltd/Ainslie, Australian Capital Territory/Australie (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 2; Pp. 190-199; Bibl. 67 ref.
LA :	Anglais
EA :	One-third of the 149 people recruited 15 to 18 years ago in the Sydney Multicentre Study of Parkinson's disease have survived. The original study compared low-dose levodopa with low-dose bromocriptine. We now report the problems experienced by people who survive 15 years from diagnosis. The standardized mortality ratio is significantly elevated at 1.86 and is not significantly different between treatment arms. Falls occur in 81% of patients, and 23% sustained fractures. Cognitive decline is present in 84%, and 48% fulfill the criteria for dementia. Hallucinations and depression are experienced by 50%. Choking has occurred in 50%, symptomatic postural hypotension in 35%, and urinary incontinence in 41%. No patient is still employed, and 40% of patients live in aged care facilities. Although approximately 95% have experienced L-dopa-induced dyskinesia/dystonia and end of dose failure of medication, in the majority, these symptoms are not disabling. Dyskinesia and dystonia were delayed by early use of bromocriptine, but end-of-dose failure appeared at a similar time once L-dopa was added. The rate of disease progression is similar in both arms of the study. We conclude that the most disabling long-term problems of Parkinson's disease relate to the emergence of symptoms that are not improved by L-dopa. Neuroprotective interventions in Parkinson's disease should be judged by their ability to improve non-L-dopa-responsive aspects of the disease, rather than just by their capacity to delay the introduction of L-dopa or reduce its associated side effects.
CC :	002B17; 002B17G; 002B17A03
FD :	Système nerveux pathologie; Etude multicentrique; Lévodopa; Parkinson maladie
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Antiparkinsonien
ED :	Nervous system diseases; Multicenter study; Levodopa; Parkinson disease
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Antiparkinson agent
SD :	Sistema nervioso patología; Estudio multicéntrico; Levodopa; Parkinson enfermedad
LO :	INIST-20953.354000126378730080
ID :	05-0151001

Links to Exploration step

Pascal:05-0151001

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Sydney multicenter study of Parkinson's disease : Non-L-dopa-responsive problems dominate at 15 years</title>
<author><name sortKey="Hely, Mariese A" sort="Hely, Mariese A" uniqKey="Hely M" first="Mariese A." last="Hely">Mariese A. Hely</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Westmead Hospital</s1>
<s2>Westmead New South Wales</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morris, John G L" sort="Morris, John G L" uniqKey="Morris J" first="John G. L." last="Morris">John G. L. Morris</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Westmead Hospital</s1>
<s2>Westmead New South Wales</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Reid, Wayne G J" sort="Reid, Wayne G J" uniqKey="Reid W" first="Wayne G. J." last="Reid">Wayne G. J. Reid</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Westmead Hospital</s1>
<s2>Westmead New South Wales</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Trafficante, Robert" sort="Trafficante, Robert" uniqKey="Trafficante R" first="Robert" last="Trafficante">Robert Trafficante</name>
<affiliation><inist:fA14 i1="02"><s1>Covance Pty Ltd</s1>
<s2>Ainslie, Australian Capital Territory</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0151001</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0151001 INIST</idno>
<idno type="RBID">Pascal:05-0151001</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001F59</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Sydney multicenter study of Parkinson's disease : Non-L-dopa-responsive problems dominate at 15 years</title>
<author><name sortKey="Hely, Mariese A" sort="Hely, Mariese A" uniqKey="Hely M" first="Mariese A." last="Hely">Mariese A. Hely</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Westmead Hospital</s1>
<s2>Westmead New South Wales</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morris, John G L" sort="Morris, John G L" uniqKey="Morris J" first="John G. L." last="Morris">John G. L. Morris</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Westmead Hospital</s1>
<s2>Westmead New South Wales</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Reid, Wayne G J" sort="Reid, Wayne G J" uniqKey="Reid W" first="Wayne G. J." last="Reid">Wayne G. J. Reid</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Westmead Hospital</s1>
<s2>Westmead New South Wales</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Trafficante, Robert" sort="Trafficante, Robert" uniqKey="Trafficante R" first="Robert" last="Trafficante">Robert Trafficante</name>
<affiliation><inist:fA14 i1="02"><s1>Covance Pty Ltd</s1>
<s2>Ainslie, Australian Capital Territory</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Levodopa</term>
<term>Multicenter study</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Etude multicentrique</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">One-third of the 149 people recruited 15 to 18 years ago in the Sydney Multicentre Study of Parkinson's disease have survived. The original study compared low-dose levodopa with low-dose bromocriptine. We now report the problems experienced by people who survive 15 years from diagnosis. The standardized mortality ratio is significantly elevated at 1.86 and is not significantly different between treatment arms. Falls occur in 81% of patients, and 23% sustained fractures. Cognitive decline is present in 84%, and 48% fulfill the criteria for dementia. Hallucinations and depression are experienced by 50%. Choking has occurred in 50%, symptomatic postural hypotension in 35%, and urinary incontinence in 41%. No patient is still employed, and 40% of patients live in aged care facilities. Although approximately 95% have experienced L-dopa-induced dyskinesia/dystonia and end of dose failure of medication, in the majority, these symptoms are not disabling. Dyskinesia and dystonia were delayed by early use of bromocriptine, but end-of-dose failure appeared at a similar time once L-dopa was added. The rate of disease progression is similar in both arms of the study. We conclude that the most disabling long-term problems of Parkinson's disease relate to the emergence of symptoms that are not improved by L-dopa. Neuroprotective interventions in Parkinson's disease should be judged by their ability to improve non-L-dopa-responsive aspects of the disease, rather than just by their capacity to delay the introduction of L-dopa or reduce its associated side effects.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>20</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Sydney multicenter study of Parkinson's disease : Non-L-dopa-responsive problems dominate at 15 years</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HELY (Mariese A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MORRIS (John G. L.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>REID (Wayne G. J.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>TRAFFICANTE (Robert)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Westmead Hospital</s1>
<s2>Westmead New South Wales</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Covance Pty Ltd</s1>
<s2>Ainslie, Australian Capital Territory</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>190-199</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000126378730080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>67 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0151001</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>One-third of the 149 people recruited 15 to 18 years ago in the Sydney Multicentre Study of Parkinson's disease have survived. The original study compared low-dose levodopa with low-dose bromocriptine. We now report the problems experienced by people who survive 15 years from diagnosis. The standardized mortality ratio is significantly elevated at 1.86 and is not significantly different between treatment arms. Falls occur in 81% of patients, and 23% sustained fractures. Cognitive decline is present in 84%, and 48% fulfill the criteria for dementia. Hallucinations and depression are experienced by 50%. Choking has occurred in 50%, symptomatic postural hypotension in 35%, and urinary incontinence in 41%. No patient is still employed, and 40% of patients live in aged care facilities. Although approximately 95% have experienced L-dopa-induced dyskinesia/dystonia and end of dose failure of medication, in the majority, these symptoms are not disabling. Dyskinesia and dystonia were delayed by early use of bromocriptine, but end-of-dose failure appeared at a similar time once L-dopa was added. The rate of disease progression is similar in both arms of the study. We conclude that the most disabling long-term problems of Parkinson's disease relate to the emergence of symptoms that are not improved by L-dopa. Neuroprotective interventions in Parkinson's disease should be judged by their ability to improve non-L-dopa-responsive aspects of the disease, rather than just by their capacity to delay the introduction of L-dopa or reduce its associated side effects.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Etude multicentrique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Multicenter study</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estudio multicéntrico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>04</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>41</s5>
</fC07>
<fN21><s1>101</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 05-0151001 INIST</NO>
<ET>Sydney multicenter study of Parkinson's disease : Non-L-dopa-responsive problems dominate at 15 years</ET>
<AU>HELY (Mariese A.); MORRIS (John G. L.); REID (Wayne G. J.); TRAFFICANTE (Robert)</AU>
<AF>Department of Neurology, Westmead Hospital/Westmead New South Wales/Australie (1 aut., 2 aut., 3 aut.); Covance Pty Ltd/Ainslie, Australian Capital Territory/Australie (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 2; Pp. 190-199; Bibl. 67 ref.</SO>
<LA>Anglais</LA>
<EA>One-third of the 149 people recruited 15 to 18 years ago in the Sydney Multicentre Study of Parkinson's disease have survived. The original study compared low-dose levodopa with low-dose bromocriptine. We now report the problems experienced by people who survive 15 years from diagnosis. The standardized mortality ratio is significantly elevated at 1.86 and is not significantly different between treatment arms. Falls occur in 81% of patients, and 23% sustained fractures. Cognitive decline is present in 84%, and 48% fulfill the criteria for dementia. Hallucinations and depression are experienced by 50%. Choking has occurred in 50%, symptomatic postural hypotension in 35%, and urinary incontinence in 41%. No patient is still employed, and 40% of patients live in aged care facilities. Although approximately 95% have experienced L-dopa-induced dyskinesia/dystonia and end of dose failure of medication, in the majority, these symptoms are not disabling. Dyskinesia and dystonia were delayed by early use of bromocriptine, but end-of-dose failure appeared at a similar time once L-dopa was added. The rate of disease progression is similar in both arms of the study. We conclude that the most disabling long-term problems of Parkinson's disease relate to the emergence of symptoms that are not improved by L-dopa. Neuroprotective interventions in Parkinson's disease should be judged by their ability to improve non-L-dopa-responsive aspects of the disease, rather than just by their capacity to delay the introduction of L-dopa or reduce its associated side effects.</EA>
<CC>002B17; 002B17G; 002B17A03</CC>
<FD>Système nerveux pathologie; Etude multicentrique; Lévodopa; Parkinson maladie</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Antiparkinsonien</FG>
<ED>Nervous system diseases; Multicenter study; Levodopa; Parkinson disease</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Antiparkinson agent</EG>
<SD>Sistema nervioso patología; Estudio multicéntrico; Levodopa; Parkinson enfermedad</SD>
<LO>INIST-20953.354000126378730080</LO>
<ID>05-0151001</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F59 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001F59 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0151001
   |texte=   Sydney multicenter study of Parkinson's disease : Non-L-dopa-responsive problems dominate at 15 years
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Sydney multicenter study of Parkinson's disease : Non-L-dopa-responsive problems dominate at 15 years

Sydney multicenter study of Parkinson's disease : Non-L-dopa-responsive problems dominate at 15 years

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri